Copyright © 2001 by the European Society of Cardiology.
Effects of dipyridamole on coronary collateralization and myocardial perfusion in patients with ischaemic cardiomyopathy
a Servizio di Cardiologia Riabilitativa, Azienda Ospedaliera ‘G.M.Lancisi’ Ancona, Italy
b Department of Medicine, University of Gainesville, Florida, U.S.A.
revised August 31, 2000; accepted September 6, 2000
Abstract
Aims There is evidence that oral dipyridamole, a nucleoside uptake blocker that increases myocardial adenosine levels, lessens myocardial ischaemia by inducing coronary collateral growth in animal models of ischaemic heart disease. However, whether dipyridamole can exert a similar effect in humans with coronary artery disease is controversial.
Methods and Results We studied 30 male patients (mean age 55±9 years) with coronary artery disease and left ventricular systolic dysfunction (ejection fraction >40%). Patients were randomized into three matched groups. Group A patients (n=10) received dipyridamole alone at a dose of 75mg t.i.d. orally for 8 weeks. Group B patients (n=10) underwent exercise training at 60% of peak O2three times a week for 8 weeks, and received dipyridamole. Group C patients (n=10) had neither exercise testing nor dipyridamole. On study entry and after 8 weeks all patients underwent an exercise test with gas exchange analysis, dobutamine stress echocardiography, 201-thallium planar myocardial scintigraphy, and coronary angiography. Peak O2increased significantly only in trained patients. Thallium uptake of the collateral-dependent myocardium, coronary collateral score and wall thickening score increased significantly only in groups receiving dipyridamole, the greatest improvement being in group B patients. Plasma adenosine levels were also the highest in group B (P<0·001 vs A and C). Correlations were found between changes in adenosine levels and increases of both thallium uptake (r=–0·70;P=0·001) and collateralization (r=0·72;P=0·001).
Conclusion Exercise training potentiates the effects of dipyridamole on coronary collateralization and myocardial perfusion in humans with ischaemic cardiomyopathy.
Key Words: Dipyridamole, adenosine, myocardial scintigraphy, ischaemic heart disease
f1 Correspondence: Romualdo Belardinelli, MD, Via Rismondo, 5, 60100 Ancona, Italy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S H Schirmer, F C van Nooijen, J J Piek, and N van Royen Stimulation of collateral artery growth: travelling further down the road to clinical application Heart, February 1, 2009; 95(3): 191 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Adair Growth regulation of the vascular system: an emerging role for adenosine Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R283 - R296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Shuralyova, P. Tajmir, P. J. Bilan, G. Sweeney, and I. R. Coe Inhibition of glucose uptake in murine cardiomyocyte cell line HL-1 by cardioprotective drugs dilazep and dipyridamole Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H627 - H632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Picano and on behalf of the PISA study group Dipyridamole in chronic stable angina pectoris. A randomized, double blind, placebo-controlled, parallel group study Eur. Heart J., October 1, 2001; 22(19): 1785 - 1793. [Abstract] [PDF]
|
|
|
|
|
|
F. Lombardi and R. Rambaldi Coronary angiogenesis: dipyridamole is back on the stage? Eur. Heart J., July 2, 2001; 22(14): 1151 - 1153. [PDF]
|
|